雷公藤多苷片抑制小鼠肾小球系膜细胞增殖的谱效分析
|
摘要
目的:探究HPLC法分析小鼠肾小球系膜细胞药效毒效的雷公藤多苷片谱效关系,为以后研发新型药物载体、开展高质量的雷公藤多甙片临床应用研究,获得高质量的临床证据,指导临床合理用药,提供理论和实验依据。方法:选择7个不同厂家生产的雷公藤多苷片作为研究对象,通过HPLC法建立高效液相指纹图谱,对不同厂家生产的雷公藤多苷片对小鼠肾小球系膜细胞增殖抑制的差异展开对比分析。结果:A厂家生产的雷公藤多苷片药效最强的同时,毒性也最强;B厂家在抗炎效果上不明显,但是毒性明显;G厂家药效不明显,而毒性中等。结论:积极控制其毒性成分含量,甄别雷公藤多甙片的有效有毒成分,筛选出治疗肾炎蛋白尿的高效无毒或少毒的单体。
Objective: To explore the efficacy of tripterygium by HPLC method on mesangial cell in rats. Methods: Tripterygium of seven different manufacturers was selected. The high performance liquid chromatography of tripterygium was established by HPLC method. The difference of inhibiting effect of different manufacturers on mesangial cell was compared. Results: Tripterygium of A manufacturers shows best efficacy and strongest toxicity. Tripterygium of B manufacturers shows inapparent anti-inflammatory effects and obvious toxicity. Tripterygium of G manufacturers shows inapparent efficacy and moderate toxicity. Conclusion: The content of toxic components of tripterygium should be actively controlled; effective toxic components need to be screened; the highly effective non-toxic or less toxic monomer treated nephritis proteinuria should be screened out.
Objective: To explore the efficacy of tripterygium by HPLC method on mesangial cell in rats. Methods: Tripterygium of seven different manufacturers was selected. The high performance liquid chromatography of tripterygium was established by HPLC method. The difference of inhibiting effect of different manufacturers on mesangial cell was compared. Results: Tripterygium of A manufacturers shows best efficacy and strongest toxicity. Tripterygium of B manufacturers shows inapparent anti-inflammatory effects and obvious toxicity. Tripterygium of G manufacturers shows inapparent efficacy and moderate toxicity. Conclusion: The content of toxic components of tripterygium should be actively controlled; effective toxic components need to be screened; the highly effective non-toxic or less toxic monomer treated nephritis proteinuria should be screened out.
引文
[1]高瑞金,姚树青,李雪梅.雷公藤多苷片联合芪胶升白胶囊对糖尿病肾病Ⅳ期患者尿蛋白、血白蛋白及肾功能的影响[J].现代中西医结合杂志,2016,25(23):2544-2546.
[2]张丽敏,李鸿燕,高燕,等.雷公藤多苷对糖尿病肾病大鼠肾损伤的保护作用及可能机制[J].中国老年学杂志,2016,36(14):3389-3391.
[3]景晓平,程伟伟,邹亚,等.雷公藤多苷对雄性幼鼠生殖损伤作用的可逆性研究[J].上海中医药大学学报,2016,30(4):65-68.
[4]王丹,赵勇,左新河.中医药治疗自身免疫性甲状腺炎的研究进展[J].江西中医药,2016,47(7):75-77.
[5]刘珊,刘伦志,覃智慧,等.雷公藤多甙对老年大鼠肾小球肾炎的疗效及炎症指标的影响[J].中国免疫学杂志,2014,30(5):627-629.
[6]李振彬,王志强,宫彩霞,等.白芍总苷对雷公藤多苷治疗狼疮性肾炎减毒增效作用的实验研究[J].中药新药与临床药理,2009,20(6):513-516.
[7]张丽春.雷公藤多苷对慢性肾炎的作用机制研究[J].南京中医药大学学报,2012,13(6):594-596.
[8]池婕,林兵,刘志宏,等.雷公藤制剂指纹图谱及谱效关系研究[J].中国中药杂志,2015,40(8):1479-1483.
[9]昊霞,林兵,王忠震,等.雷公藤的免疫抑制活性及毒性的谱效关系研究[J].中国医院药学杂志,2016,36(7):547-552.
[10]刘雪梅,林兵,刘志宏,等.雷公藤制剂抑制小鼠耳肿胀谱效关系研究[J].中成药,2016,38(2):425-427.
[11]刘廷,王海丹,狄留庆,等.基于甲型H1N1流感病毒致MDCK细胞损伤保护作用的双黄连组方HPLC特征图谱谱效关系研究[J].中国中药杂志,2015,40(21):4194-4199.
[12]窦志华,罗琳,候金燕,等.基于含药血清经时谱效关系的茵陈蒿汤保肝作用药效物质研究[J].中国医院药学杂志,2017,37(13):1232-1237.
[13]赵小梅,浦仕彪,赵庆国,等.基于谱-效相关分析的雷公藤致肝毒性物质基础的初步研究[J].中国中药杂志,2016,41(15):2915-2921.
[2]张丽敏,李鸿燕,高燕,等.雷公藤多苷对糖尿病肾病大鼠肾损伤的保护作用及可能机制[J].中国老年学杂志,2016,36(14):3389-3391.
[3]景晓平,程伟伟,邹亚,等.雷公藤多苷对雄性幼鼠生殖损伤作用的可逆性研究[J].上海中医药大学学报,2016,30(4):65-68.
[4]王丹,赵勇,左新河.中医药治疗自身免疫性甲状腺炎的研究进展[J].江西中医药,2016,47(7):75-77.
[5]刘珊,刘伦志,覃智慧,等.雷公藤多甙对老年大鼠肾小球肾炎的疗效及炎症指标的影响[J].中国免疫学杂志,2014,30(5):627-629.
[6]李振彬,王志强,宫彩霞,等.白芍总苷对雷公藤多苷治疗狼疮性肾炎减毒增效作用的实验研究[J].中药新药与临床药理,2009,20(6):513-516.
[7]张丽春.雷公藤多苷对慢性肾炎的作用机制研究[J].南京中医药大学学报,2012,13(6):594-596.
[8]池婕,林兵,刘志宏,等.雷公藤制剂指纹图谱及谱效关系研究[J].中国中药杂志,2015,40(8):1479-1483.
[9]昊霞,林兵,王忠震,等.雷公藤的免疫抑制活性及毒性的谱效关系研究[J].中国医院药学杂志,2016,36(7):547-552.
[10]刘雪梅,林兵,刘志宏,等.雷公藤制剂抑制小鼠耳肿胀谱效关系研究[J].中成药,2016,38(2):425-427.
[11]刘廷,王海丹,狄留庆,等.基于甲型H1N1流感病毒致MDCK细胞损伤保护作用的双黄连组方HPLC特征图谱谱效关系研究[J].中国中药杂志,2015,40(21):4194-4199.
[12]窦志华,罗琳,候金燕,等.基于含药血清经时谱效关系的茵陈蒿汤保肝作用药效物质研究[J].中国医院药学杂志,2017,37(13):1232-1237.
[13]赵小梅,浦仕彪,赵庆国,等.基于谱-效相关分析的雷公藤致肝毒性物质基础的初步研究[J].中国中药杂志,2016,41(15):2915-2921.